Do we need more drugs to treat heart failure? Differences between clinical trials and clinical practice;¿Se necesitan más fármacos para el tratamiento de la insuficiencia cardiaca? Diferencias entre los ensayos clínicos y la práctica clínica

Revista Espanola de Cardiologia Suplementos

Volumn 6, Issue C, 2006, Pages

  Soler Soler, Jordi ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Clinical trials; Heart failure; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADRENERGIC SYSTEM; CARDIAC PATIENT; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; HEART FAILURE; HUMAN; LONG TERM CARE; METHODOLOGY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 35948944955     PISSN: 11313587     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Permanyer-Miralda G, Soriano N, Brotons C, Moral I, Pinar J, Cascant P, et al. Características basales y determinantes de la evolución en pacientes ingresados por insuficiencia cardiaca en un hospital general. Rev Esp Cardiol. 2002;55:571-8.
2. MacIntyre K, Capewell S, Stewart JWT, Chalmers J, Boyd A, Finlayson A, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation. 2000;102:1126-31.
3. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More malignant that cancer? Five-year survival following a first admission for heart failure. Eur J Heart Failure. 2001;3:315-22.
4. Lenzen MJ, Boersma E, Scholte OP, Reimer WJ, Balk AH, Komajda M, et al. Under utilization of evidence based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure J. 2005;26:2706-13.
5. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13.
6. Mehra MR, Uber PA, Francis GS. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? J Am Coll Cardiol. 2003;41:1606-10.
7. Orn S, Dickstein K. Neurohormonal inhibition in heart failure, is there a limit. Eur Heart J. 2003;24:1705-6.
8. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev. 2004;9:63-79.
9. Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, et al. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation. 2005;112:3408-14.
10. Malkin CJ, Pugh PJ, West JN, Ven Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind raandomized placebo controlled trial. Euyr Heart J. 2006;27:57-64.
11. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al; for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-71.
12. Pitt B, Poole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-7.
13. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-75.
14. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115-40.
15. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult-Summary Article. J Am Coll Cardiol. 2005;46:1116-43.
16. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Pérez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17.
17. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al; for the CHARM Investigators. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-81.
18. Flather M, Shibata M, Coats A, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al; on behalf of the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
19. Masoudi FA, Havranek EP, Wolfe P, Gross CP, Rathore SS, Steiner JF, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003;146:250-7.
20. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komadja M, et al. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology: Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: reply [carta]. Eur Heart J. 2005;26:2473-4.